Reportlinker.com

Reportlinker.com

April 16, 2008 05:02 ET

Get a Deep Insight Into the Future of Targeted Therapeutics: Key Technologies, New Therapy Area Applications and Leading Players

LONDON, UNITED KINGDOM--(Marketwire - April 16, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players

In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules. The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry. The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players is a new report published by Business Insights that examines various types of targeted therapy within pharma pipelines, highlighting the molecules of greatest significance to major therapy areas. The key revenue drivers and product focus within targeted technology markets are also assessed. This report also measures the impact of the new model of targeted therapeutic development upon stakeholder demand and health economics. Discover the most promising targeted molecules within each therapeutic area, identify the pipeline potential of leading companies and align your R&D strategies with the latest innovations and development models...

Table of Contents

The Future of Targeted Therapeutics

Executive Summary 10

Emergence of targeted therapeutics 10

Analysis of stakeholder incentives 11

Types of targeted therapeutics 12

Role of targeted therapeutics in selected therapy areas 13

Chapter 1 Emergence of targeted

therapeutics 16

Summary 16

Introduction 17

Decline of the blockbuster model 18

The "nichebuster" model 22

The emergence of targeted therapeutics 23

Convergence of biotechnology and pharmaceutical companies 25

Licensing incentives 26

Risk management 29

Role of biomarkers and diagnostics 32

Academic research and technology transfer 34

Chapter 2 Analysis of stakeholder

incentives 36

Summary 36

Introduction 37

Institutional payors 37

Regulators 39

Patients and patient advocacy groups 41

Physicians 43

Pharmaceutical companies 44

Chapter 3 Types of targeted therapeutics 48

Summary 48

Introduction 49

Innovative small molecules 49

Mechanism of action 50

Examples 52

Gleevec 52

Lapatinib (Tykerd/Tyverb) 52

SNS-032 53

PLX4032 53

Market synopsis 53

Protein/Peptide drugs 54

Mechanism of action 55

Examples 57

AGRO100 57

PRX321 58

Market synopsis 58

Monoclonal antibodies and antibody-like structures 60

Mechanism of action 60

Examples 62

Rituximab (Rituxan) 62

Alemtuzumab (Campath) 62

Erbitux/cetuximab 63

Avastin/bevacizumab 64

Herceptin/trastuzumab 64

Ibritumomab tiuxetan (Zevalin) 65

Tositumomab (Bexxar) 65

Market synopsis 65

Nucleic acid therapies 67

Mechanism of action 68

Examples 68

Genasense (oblimersen sodium) 68

Nexagon 69

4-Thio FAC 69

Market synopsis 69

RNA interference 70

Mechanism of action 70

Examples 72

CALAA-01 72

siRNA AV-34 72

Bioral SiRNA 72

Market synopsis 72

Stem cell therapies 73

Market synopsis 74

Future therapeutic applications 74

Regulatory concerns 76

Gene therapy 76

Drug delivery and nanotechnology in targeted therapeutics 77

Mechanism of action 78

Examples 79

BioVant 79

ATI-1123 (docetaxel) 80

Rexin-G 80

Abraxane 80

131I-TM-601 81

Market synopsis 81

Conclusion 83

Chapter 4 Role of targeted therapeutics in selected therapy areas 86

Summary 86

The cancer market 87

Targeting cancer cells for destruction 88

Blocking growth signalling pathways 88

Epidemiology 88

Current treatments 90

Unmet needs and innovation 96

Medical Needs 96

High toxicity and side effect profiles 96

Variable efficacy rates 96

The multifactorial nature of disease 96

Targeting brain tumors 97

Economic Needs 97

Reimbursement policies 97

Targeted therapeutics in cancer 99

Antineoplastics 100

Innovative small molecule therapies 101

Monoclonal antibody therapies 102

Proteins and Peptides 103

Application of genetic technology 103

RNAi in cancer 104

Applications of nanotechnology 106

Novel drug delivery approaches 107

The Cardiovascular Market 108

Epidemiology 108

Current market scenario 109

Unmet needs and innovation 111

Pill burden and patient compliance 111

Inefficient mechanism of action 111

Drug delivery technology limitations 111

Targeted therapeutics in cardiovascular diseases 113

Protein and nucleic acid therapies 113

Targeted small molecule drugs 113

Monoclonal antibody therapies 114

Stem cells 114

Nanotechnology 115

The CNS Market 117

Epidemiology 118

Current treatments 120

Unmet needs and innovation 121

Crossing the blood-brain barrier 122

Improving specificity and affinity 122

Accuracy in determining drug bioavailability 123

Improved side effect profiles 123

Appropriate clinical trial design - defining target patient subsets 124

Diagnosis-specific unmet needs 124

Depression 124

Schizophrenia 124

Sleep disorders 125

Alzheimer's disease and other dementias 125

Epilepsy 125

Parkinson's disease and movement disorders 126

Pain therapeutics 126

Targeted therapeutics in CNS 127

Innovative small molecules 128

Nucleic acid therapies 129

Monoclonal antibodies 130

Stem cell and gene therapy 131

Novel therapeutic mechanisms of action 134

Synthetic toxins 134

Targeted viral delivery systems 134

Innovative diagnostic devices 135

The Infectious Diseases Market 136

Epidemiology 136

Viral Infections 137

Hepatitis 137

Influenza 138

Herpes simplex virus 139

Bacterial infections 139

Fungal infections 140

Current market scenario 140

Unmet Needs and Innovations 141

Efficacy 141

Emerging resistance to existing treatments and lack of innovation 142

Immunoglobin (vaccination) drug delivery mechanisms 143

Targeted therapeutics in infectious diseases 143

Innovative small molecules 143

Applications of genetic technology 145

Therapeutic proteins and peptides 146

RNAi in infectious diseases 146

Antibodies 148

Novel targeted drug delivery mechanisms 150

Chapter 5 Appendix 151

Research methodology 151

ATC Codes 151

Cancer Therapies 151

Antineoplastic and immunomodulating agents 151

L1: Cytostatics 151

L2: Cytostatic hormone therapy 151

L3: Immunostimulating agents 152

Cardiovascular Therapies 152

B1: Anti-thrombotic agents 152

C1: Cardiac Therapy 152

C2 Antihypertensives 152

C3 Diuretics 152

C7 Beta Blockers 152

C8 Calcium antagonists 152

C9 Agents acting on the renin-angiotensin system 152

C10 Hypolipidaemics/Anti-Atheroma Preparations 152

Index 153

List of Figures

Figure 1.1: Forecast growth for the top 20 biopharmaceutical companies, 2006-12 21

Figure 1.2: Evolution of the biopharmaceutical corporation 28

Figure 1.3: Reliance on licensed products vs. forecast revenue growth, top 20 pharmaceutical firms, 2006-12 29

Figure 1.4: FDA new drug approvals and Phase 3 failures, 2006-2007 31

Figure 2.5: Typical health economic value proposition for innovative or personalized therapies 39

Figure 3.6: Mechanism of action of targeted small-molecule inhibitors 51

Figure 3.7: Schematic presentation of targeted delivery of therapeutic proteins and peptides to antigen-positive tumor cells or tumor vasculature 57

Figure 3.8: Mechanism of action of monoclonal antibodies 61

Figure 3.9: Mechanism of post-transcriptional gene silencing by siRNA 71

Figure 4.10: Global cancer innovatives market, 2003-2006 94

Figure 4.11: Targeted oncology pipeline by indication, 2006 100

List of Tables

Table 1.1: Global revenues from blockbuster drugs, top 10 pharma companies, 2006 ($m) 20

Table 1.2: Complementary strengths of pharma and biotech companies 25

Table 4.3: Estimated annual incidence of cancer diagnoses ('000s), global, 2002 census 89

Table 4.4: Breakdown of the global antineoplastic market by drug class, 92

Table 4.5: Leading therapies in the global antineoplastics market, 2005-07 93

Table 4.6: Antineoplastic sales forecast, 2006-12 101

Table 4.7: Chemotherapeutic siRNA targets in drug development pipelines 105

Table 4.8: Key pipeline oncology drugs and technologies utilizing nanotechnology, 2008 106

Table 4.9: Estimated prevalence of CVD across the seven major markets, 2006 109

Table 4.10: Breakdown of the global CVD market by drug class, 2003-07 110

Table 4.11: Estimated prevalence of CNS disorders across the seven major markets, 2006 118

Table 4.12: Global sales of CNS products by disease indication, 2005-2007, $m 120

Table 4.13: Top 10 CNS brands, sales revenues, global, 2007, $m 121

Table 4.14: Medicinal chemical properties of a successful CNS drug 123

Table 4.15: Estimated prevalence of infective diseases across seven major markets, 2005 137

Table 4.16: The anti-infectives market, global sales revenues, 2003-2007, $m 141

To order this report:

The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players

More market research reports here!

Contact Nicolas: nbo@reportlinker.com Phone: +1 718-887-3024

Contact Information